226 related articles for article (PubMed ID: 32513388)
1. Modulation of dopamine D
Moreno-Delgado D; Puigdellívol M; Moreno E; Rodríguez-Ruiz M; Botta J; Gasperini P; Chiarlone A; Howell LA; Scarselli M; Casadó V; Cortés A; Ferré S; Guzmán M; Lluís C; Alberch J; Canela EI; Ginés S; McCormick PJ
Elife; 2020 Jun; 9():. PubMed ID: 32513388
[TBL] [Abstract][Full Text] [Related]
2. Heteroreceptor Complexes Formed by Dopamine D
Rodríguez-Ruiz M; Moreno E; Moreno-Delgado D; Navarro G; Mallol J; Cortés A; Lluís C; Canela EI; Casadó V; McCormick PJ; Franco R
Mol Neurobiol; 2017 Aug; 54(6):4537-4550. PubMed ID: 27370794
[TBL] [Abstract][Full Text] [Related]
3. The histamine H3 receptor modulates dopamine D2 receptor-dependent signaling pathways and mouse behaviors.
Xu J; Pittenger C
J Biol Chem; 2023 Apr; 299(4):104583. PubMed ID: 36871761
[TBL] [Abstract][Full Text] [Related]
4. Hyperactivation of D1 and A2A receptors contributes to cognitive dysfunction in Huntington's disease.
Tyebji S; Saavedra A; Canas PM; Pliassova A; Delgado-García JM; Alberch J; Cunha RA; Gruart A; Pérez-Navarro E
Neurobiol Dis; 2015 Feb; 74():41-57. PubMed ID: 25449908
[TBL] [Abstract][Full Text] [Related]
5. The Histamine H3 Receptor Differentially Modulates Mitogen-activated Protein Kinase (MAPK) and Akt Signaling in Striatonigral and Striatopallidal Neurons.
Rapanelli M; Frick LR; Horn KD; Schwarcz RC; Pogorelov V; Nairn AC; Pittenger C
J Biol Chem; 2016 Sep; 291(40):21042-21052. PubMed ID: 27510032
[TBL] [Abstract][Full Text] [Related]
6. Histamine H
Aquino-Miranda G; Rivera-Ramírez N; Márquez-Gómez R; Escamilla-Sánchez J; González-Pantoja R; Ramos-Languren LE; Perez-Neri I; Bueno-Nava A; Ríos C; Arias-Montaño JA
Prog Neuropsychopharmacol Biol Psychiatry; 2019 Aug; 94():109653. PubMed ID: 31108178
[TBL] [Abstract][Full Text] [Related]
7. Dopamine D1-histamine H3 receptor heteromers provide a selective link to MAPK signaling in GABAergic neurons of the direct striatal pathway.
Moreno E; Hoffmann H; Gonzalez-Sepúlveda M; Navarro G; Casadó V; Cortés A; Mallol J; Vignes M; McCormick PJ; Canela EI; Lluís C; Moratalla R; Ferré S; Ortiz J; Franco R
J Biol Chem; 2011 Feb; 286(7):5846-54. PubMed ID: 21173143
[TBL] [Abstract][Full Text] [Related]
8. Histamine H3 receptor activation prevents dopamine D1 receptor-mediated inhibition of dopamine release in the rat striatum: a microdialysis study.
Alfaro-Rodriguez A; Alonso-Spilsbury M; Arch-Tirado E; Gonzalez-Pina R; Arias-Montaño JA; Bueno-Nava A
Neurosci Lett; 2013 Sep; 552():5-9. PubMed ID: 23896530
[TBL] [Abstract][Full Text] [Related]
9. Sexually dimorphic dopaminergic dysfunction in a transgenic mouse model of Huntington's disease.
Renoir T; Argyropoulos A; Chevarin C; Lanfumey L; Hannan AJ
Pharmacol Biochem Behav; 2014 Dec; 127():15-20. PubMed ID: 25316307
[TBL] [Abstract][Full Text] [Related]
10. Possible use of a H3R antagonist for the management of nonmotor symptoms in the Q175 mouse model of Huntington's disease.
Whittaker DS; Wang HB; Loh DH; Cachope R; Colwell CS
Pharmacol Res Perspect; 2017 Oct; 5(5):. PubMed ID: 28971617
[TBL] [Abstract][Full Text] [Related]
11. Kinetic Modelling and Test-Retest Reproducibility for the Dopamine D
Bertoglio D; Verhaeghe J; Miranda A; Wyffels L; Stroobants S; Dominguez C; Munoz-Sanjuan I; Skinbjerg M; Liu L; Staelens S
Mol Imaging Biol; 2021 Apr; 23(2):208-219. PubMed ID: 33179158
[TBL] [Abstract][Full Text] [Related]
12. Differential D1 and D2 receptor-mediated effects on immediate early gene induction in a transgenic mouse model of Huntington's disease.
Spektor BS; Miller DW; Hollingsworth ZR; Kaneko YA; Solano SM; Johnson JM; Penney JB; Young AB; Luthi-Carter R
Brain Res Mol Brain Res; 2002 Jun; 102(1-2):118-28. PubMed ID: 12191502
[TBL] [Abstract][Full Text] [Related]
13. Changes in Dopamine Signalling Do Not Underlie Aberrant Hippocampal Plasticity in a Mouse Model of Huntington's Disease.
Dallérac GM; Cummings DM; Hirst MC; Milnerwood AJ; Murphy KP
Neuromolecular Med; 2016 Mar; 18(1):146-53. PubMed ID: 26782175
[TBL] [Abstract][Full Text] [Related]
14. Dopaminergic signaling and striatal neurodegeneration in Huntington's disease.
Tang TS; Chen X; Liu J; Bezprozvanny I
J Neurosci; 2007 Jul; 27(30):7899-910. PubMed ID: 17652581
[TBL] [Abstract][Full Text] [Related]
15. Marked changes in signal transduction upon heteromerization of dopamine D1 and histamine H3 receptors.
Ferrada C; Moreno E; Casadó V; Bongers G; Cortés A; Mallol J; Canela EI; Leurs R; Ferré S; Lluís C; Franco R
Br J Pharmacol; 2009 May; 157(1):64-75. PubMed ID: 19413572
[TBL] [Abstract][Full Text] [Related]
16. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease.
Dowie MJ; Bradshaw HB; Howard ML; Nicholson LF; Faull RL; Hannan AJ; Glass M
Neuroscience; 2009 Sep; 163(1):456-65. PubMed ID: 19524019
[TBL] [Abstract][Full Text] [Related]
17. Histamine H3 Receptor Regulates Sensorimotor Gating and Dopaminergic Signaling in the Striatum.
Kononoff Vanhanen J; Nuutinen S; Tuominen M; Panula P
J Pharmacol Exp Ther; 2016 May; 357(2):264-72. PubMed ID: 26945087
[TBL] [Abstract][Full Text] [Related]
18. The magnificent two: histamine and the H3 receptor as key modulators of striatal circuitry.
Rapanelli M
Prog Neuropsychopharmacol Biol Psychiatry; 2017 Feb; 73():36-40. PubMed ID: 27773554
[TBL] [Abstract][Full Text] [Related]
19. Biased G Protein-Independent Signaling of Dopamine D
Guitart X; Moreno E; Rea W; Sánchez-Soto M; Cai NS; Quiroz C; Kumar V; Bourque L; Cortés A; Canela EI; Bishop C; Newman AH; Casadó V; Ferré S
Mol Neurobiol; 2019 Oct; 56(10):6756-6769. PubMed ID: 30919214
[TBL] [Abstract][Full Text] [Related]
20. Dopaminergic and glutamatergic signaling crosstalk in Huntington's disease neurodegeneration: the role of p25/cyclin-dependent kinase 5.
Paoletti P; Vila I; Rifé M; Lizcano JM; Alberch J; Ginés S
J Neurosci; 2008 Oct; 28(40):10090-101. PubMed ID: 18829967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
